SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-24-000124
Filing Date
2024-03-04
Accepted
2024-03-04 17:44:26
Documents
1
Period of Report
2024-03-01

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3971
  Complete submission text file 0001610717-24-000124.txt   5452
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Issuer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
McClure Matthew W. (Reporting) CIK: 0001927121 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39617 | Film No.: 24716636